Lynk Pharmaceuticals Co., Ltd.

凌科药业（浙江）股份有限公司

Clinical-stage biotech developing small-molecule JAK and TYK2 inhibitors for autoimmune and inflammatory diseases, with two core drug candidates in clinical development and a pipeline of additional preclinical programs, based in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Key long-term agreements
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Non-recurring gains and losses
• Chapter 18A biotech